IriSys LLC, a San Diego-based pharmaceutical contract development and manufacturing organization, announced Wednesday that it was awarded a five-year contract worth up to $3 million by the National Cancer Institute (NCI).
The contract is associated with the NCI’s Developmental Therapeutic Program of the Division of Cancer Treatment and Diagnosis. As part of the contract, IriSys will be developing new therapeutic agents for use in clinical trials supported by NCI.
Under this agreement, IriSys will be supplying NCI with oral, topical and injectable dosage forms to be used in NCI-sponsored and/or investigator-initiated clinical trials in humans. IriSys will be responsible for formulation studies, process optimization, manufacture of the clinical dosage forms, release testing, quality control and quality assurance.